DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

DiaMedica Therapeutics (NASDAQ: DMAC) announced a poster presentation at the 11th European Stroke Organisation Conference (ESOC 2025) in Helsinki, Finland from May 21-23, 2025.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/14/2025 - 04:30 PM

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today a poster presentation of the safety and clinical outcomes for ReMEDy2 study, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the 11^th European Stroke Organisation Conference – ESOC 2025 being held in Helsinki, Finland from May 21-23, 2025. For information about the event, visit: https://eso-stroke.org/esoc2025/.

The DiaMedica poster is:

Poster Title:

"Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only"

The poster is P-704. On Thursday May 22, 2025, John J. Volpi, MD, ReMEDy2 trial Scientific Advisory Board Member, will be present to answer questions about the poster. Following the session, a reprint of the poster will be accessible from DiaMedica’s website at: https://www.diamedica.com/investors/events-presentations.

DiaMedica will also be exhibiting at the conference located in the exhibition hall at booth D4.1.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.